Combination therapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has grown after earlier treatment. It aims to see if adding these drugs can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery.
- Your cancer has gotten worse after one or two lines of treatment, and your first treatment included a platinum drug and a fluorouracil drug, with or without an immunotherapy drug.
- You have at least one tumor that can be measured on a scan.
- Your cancer has a certain level of HER2 protein (2+ or 3+ for one group, or 1+ for another group).
- Your organs and bone marrow are working well enough to receive the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—disitamab vedotin, tunlametinib, and a PD-1 antibody—for people with advanced stomach cancer that has HER2 (a protein that helps cancer grow). The goal is to see if this combo can shrink tumors or slow the cancer, and whether it's safe.
Hear when a new Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.